Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer

Status unconfirmed · Phase 2

Conditions studied: Adenocarincoma of Pancreas, Stage III Pancreatic Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, oxaliplatin, leucovorin and 5-fluoruracil, work in different ways separately and in combination to stop tumor cells from dividing so they stop growing or die. The use of metronomic dosing of chemotherapy minimizes side effects and increases efficacy by anti-angiogenic effects. The pilot study demonstrated promising responses in all patients. It is not yet known how effective this drug and dosing combination is in treating advanced pancreatic cancer. PURPOSE: This non-randomized phase II trial is studying giving weekly doses of paclitaxel, oxaliplatin, leucovorin and 5-fluorouracil together as second or third-line therapy in treating patient with locally advanced unresectable or metastatic adenocarcinoma of the pancreas following demonstrated progression after first-line gemcitabine.

Key facts

Study ID

NCT00323583

Run by

Seattle Cancer Treatment and Wellness Center

People needed

80

Starts

2006-05-01

Last updated by the study team

2007-05-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Performance state >=3
• Uncontrolled serious concomitant disease
• Radiotherapy within the 6 weeks before Cycle 1' Day 1
• Surgery within the 2 weeks before Cycle 1' Day 1

Where it is running

• Seattle Cancer Treatment and Wellness Center — Seattle, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.